0 item(s)
View cart
You have no items in your shopping cart.
Peptide
N-Acetyloxytocin - Biofargo
Background Introduction Description N-Acyloxytocin is a synthetic peptide analog of oxytocin with modified chemical properties. This compound is used for research purposes in various fields, including pharmacology, hormone interaction studies,...
$496.00
Tirzepatide ILE12NVA (NVA-ILE) substituents - Biofargo
Description Background Introduction Tirzepatide, a groundbreaking dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, has set a new standard in the treatment of type 2...
$496.00
Tirzepatide D-SER32(S32 racemized) impurity - Biofargo
Description Background Introduction Tirzepatide, a groundbreaking dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, has set a new standard in the treatment of type 2...
$496.00
Tirzepatide L-isoAsp9 impurity - Biofargo
Description Background Introduction Tirzepatide, a groundbreaking dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, has set a new standard in the treatment of type 2...
$496.00
Tirzepatide C-terminal deamidation of impurities - Biofargo
Description Background Introduction Tirzepatide, a groundbreaking dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, has set a new standard in the treatment of type 2...
$496.00
Tirzepatide L-isoAsp15 impurity - Biofargo
Description Background Introduction Tirzepatide, a groundbreaking dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, has set a new standard in the treatment of type 2...
$496.00
Tirzepatide GLN19(Q19) deamidation of impurities - Biofargo
Description Background Introduction Tirzepatide, a groundbreaking dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, has set a new standard in the treatment of type 2...
$496.00
Tirzepatide GLN24(Q24) deamidation of impurities - Biofargo
Description Background Introduction Tirzepatide, a groundbreaking dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, has set a new standard in the treatment of type 2...
$496.00
